May 18, 2020
Atlanta, Georgia – U.S.-based medical device company, Visioneering Technologies Inc. recently shared its new MyChild & Myopia education materials to help facilitate a conversation with eye care practitioners on risks of childhood myopia with parents.
Pediatric myopia, or nearsightedness in children, has undergone explosive growth on a global scale over the past four decades and has become a major worldwide eye health issue. Eye experts generally believe that minimizing the progression of nearsightedness is an important intervention aimed at minimizing life-time risks of blindness and other serious ocular diseases that are related to nearsightedness.
The new MyChild & Myopia brochure helps parents better understand myopia, its causes and ways their practitioner may be able to help slow or manage their child’s myopia.
Tony Sommer, senior vice president, sales and marketing, commented, “We are pleased to share these educational materials with our practitioners. We firmly believe that our role as a business partner in this fight is to help practitioners educate their patients about the possible effects of myopia and open the door to a positive conversation which may result in a management plan for their children.”
It’s even more important now, as practitioners focus on rebuilding their practices that they reevaluate the companies that support them with the technology and tools for continued success.
About Visioneering Technologies Inc.
Visioneering Technologies Inc. (ASX: VTI) is an innovative eye care company committed to redefining vision. Since its founding in 2008, Visioneering has brought together clinical, marketing, engineering, manufacturing and regulatory leaders from top vision care businesses to provide new solutions for presbyopia, myopia and astigmatism.
Headquartered in the U.S., Visioneering designs, manufactures, sells and distributes contact lenses. VTI has expanded its portfolio of technologies to address a range of eye care issues. The company has grown operations across North America, Australia and Europe and is expanding into Asia with a focus on markets with high rates of myopia.